Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
Abstract Background The prognosis of non-small-cell lung cancer (NSCLC) with brain metastases is very poor. Currently, therapeutic methods for this patient population include whole-brain radiation therapy (WBRT), surgery, radiosurgery and systemic treatment. Epidermal growth factor receptor tyrosine...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-020-6543-y |
| _version_ | 1818642966906929152 |
|---|---|
| author | Kejun Liu Guanming Jiang Ailing Zhang Zhuanghua Li Jun Jia |
| author_facet | Kejun Liu Guanming Jiang Ailing Zhang Zhuanghua Li Jun Jia |
| author_sort | Kejun Liu |
| collection | DOAJ |
| description | Abstract Background The prognosis of non-small-cell lung cancer (NSCLC) with brain metastases is very poor. Currently, therapeutic methods for this patient population include whole-brain radiation therapy (WBRT), surgery, radiosurgery and systemic treatment. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) could be effective on cerebral metastases of mutated NSCLC. However, which EGFR-TKIs is more appropriate is still unknown. Methods We conducted a retrospective analysis of advanced NSCLC patients with brain metastases for EGFR targeted therapy from November 2013 to April 2018 at Dongguan People’s Hospital, Southern Medical University, China. A total of 43 patients were recruit in this study. Among them, 21 cases received icotinib (125 mg, thrice a day) and 22 cases received gefitinib (250 mg, once a day) until disease progression or unacceptable toxicity. The primary end point of this study was intracranial PFS (iPFS). The relationships between therapeutic arms and patients characteristics were performed using Pearson’s chi-square test or Fisher’s exact test. The differences in PFS among the two arms were analyzed using Kaplan-Meier curves and log rank tests. Results There was no significant difference of intracranial ORR (66.6% versus 59.1%, P = 0.62) and DCR (85.7% versus 81.8%, P = 0.73) between the two arms. The median intracranial PFS (iPFS) for icotinib and gefitinib arms were 8.4 months (95% CI, 5.4 to 11.3 months) and 10.6 months (95% CI, 6.3 to 14.8 months), respectively (P = 0.17). Adverse events of the two study arms were generally mild. None of the patients experienced dose reduction of EGFR-TKIs. Conclusions Our study showed that icotinib and gefitinib had similar efficacy for brain metastasis of EGFR mutated NSCLC. Large randomized studies are suggested to further illuminate the effect of these two EGFR-TKIs on cerebral lesions of NSCLC. |
| first_indexed | 2024-12-16T23:51:28Z |
| format | Article |
| id | doaj.art-80d72848b36d4270a641025181c5b31b |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-16T23:51:28Z |
| publishDate | 2020-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-80d72848b36d4270a641025181c5b31b2022-12-21T22:11:19ZengBMCBMC Cancer1471-24072020-01-012011810.1186/s12885-020-6543-yIcotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancerKejun Liu0Guanming Jiang1Ailing Zhang2Zhuanghua Li3Jun Jia4Department of Oncology, Dongguan Institute for Clinical Cancer Research, Dongguan People’s Hospital, Southern Medical UniversityDepartment of Oncology, Dongguan Institute for Clinical Cancer Research, Dongguan People’s Hospital, Southern Medical UniversityDepartment of Galactophore, Dongguan Institute for Clinical Cancer Research, Dongguan People’s Hospital, Southern Medical UniversityDepartment of Oncology, Dongguan Institute for Clinical Cancer Research, Dongguan People’s Hospital, Southern Medical UniversityDepartment of Oncology, Dongguan Institute for Clinical Cancer Research, Dongguan People’s Hospital, Southern Medical UniversityAbstract Background The prognosis of non-small-cell lung cancer (NSCLC) with brain metastases is very poor. Currently, therapeutic methods for this patient population include whole-brain radiation therapy (WBRT), surgery, radiosurgery and systemic treatment. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) could be effective on cerebral metastases of mutated NSCLC. However, which EGFR-TKIs is more appropriate is still unknown. Methods We conducted a retrospective analysis of advanced NSCLC patients with brain metastases for EGFR targeted therapy from November 2013 to April 2018 at Dongguan People’s Hospital, Southern Medical University, China. A total of 43 patients were recruit in this study. Among them, 21 cases received icotinib (125 mg, thrice a day) and 22 cases received gefitinib (250 mg, once a day) until disease progression or unacceptable toxicity. The primary end point of this study was intracranial PFS (iPFS). The relationships between therapeutic arms and patients characteristics were performed using Pearson’s chi-square test or Fisher’s exact test. The differences in PFS among the two arms were analyzed using Kaplan-Meier curves and log rank tests. Results There was no significant difference of intracranial ORR (66.6% versus 59.1%, P = 0.62) and DCR (85.7% versus 81.8%, P = 0.73) between the two arms. The median intracranial PFS (iPFS) for icotinib and gefitinib arms were 8.4 months (95% CI, 5.4 to 11.3 months) and 10.6 months (95% CI, 6.3 to 14.8 months), respectively (P = 0.17). Adverse events of the two study arms were generally mild. None of the patients experienced dose reduction of EGFR-TKIs. Conclusions Our study showed that icotinib and gefitinib had similar efficacy for brain metastasis of EGFR mutated NSCLC. Large randomized studies are suggested to further illuminate the effect of these two EGFR-TKIs on cerebral lesions of NSCLC.https://doi.org/10.1186/s12885-020-6543-yBrain metastasisEGFR mutationTargeted therapyNon-small-cell lung cancer (NSCLC) |
| spellingShingle | Kejun Liu Guanming Jiang Ailing Zhang Zhuanghua Li Jun Jia Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer BMC Cancer Brain metastasis EGFR mutation Targeted therapy Non-small-cell lung cancer (NSCLC) |
| title | Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer |
| title_full | Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer |
| title_fullStr | Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer |
| title_full_unstemmed | Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer |
| title_short | Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer |
| title_sort | icotinib is as efficacious as gefitinib for brain metastasis of egfr mutated non small cell lung cancer |
| topic | Brain metastasis EGFR mutation Targeted therapy Non-small-cell lung cancer (NSCLC) |
| url | https://doi.org/10.1186/s12885-020-6543-y |
| work_keys_str_mv | AT kejunliu icotinibisasefficaciousasgefitinibforbrainmetastasisofegfrmutatednonsmallcelllungcancer AT guanmingjiang icotinibisasefficaciousasgefitinibforbrainmetastasisofegfrmutatednonsmallcelllungcancer AT ailingzhang icotinibisasefficaciousasgefitinibforbrainmetastasisofegfrmutatednonsmallcelllungcancer AT zhuanghuali icotinibisasefficaciousasgefitinibforbrainmetastasisofegfrmutatednonsmallcelllungcancer AT junjia icotinibisasefficaciousasgefitinibforbrainmetastasisofegfrmutatednonsmallcelllungcancer |